Background: According to the International Classification of Headache Disorders (ICHD)-2, primary daily headaches unremitting from onset are classified as new daily-persistent headache (NDPH) only if migraine features are absent. When migraine features are present, classification is problematic.
1986, 6 some of his patients had migraine features, and the majority of his patients achieved complete headache resolution within a 2-year time period.
Subsequent case series have shown that NDPH can persist for years, often becoming refractory to treatment. 7 Operational diagnostic criteria for NDPH were proposed in 1994 8 but the condition was not included in the International Classification of Headache Disorders until 2004 (ICHD-2). 9 The ICHD-2 criteria, unlike the predecessor criteria, exclude patients who have prominent migraine features (table 1). In published case series, migraine features such as throbbing pain, nausea, vomiting, photophobia, and phonophobia are common. 5, 10, 11 Several series have used the original Silberstein-Lipton criteria, which only require an average of 15 or more days of monthly headache, 8 or modified ICHD-2 criteria (table 1). 5 The ICHD-2 criteria for NDPH are problematic as patients with otherwise typical NDPH are not easily classified in the presence of migraine features.
Accordingly, we studied a group of patients with primary headaches that were daily from onset using criteria for NDPH that do not exclude migraine features (NDPH-R). The objective of this study was to gain a greater understanding of the clinical features and prognosis of patients presenting with CDH from headache onset. We examined a large series of consecutive patients presenting with NDPH to our headache center, and compared patients fulfilling ICHD-2 criteria to patients with migraine features, based on epidemiologic profiles, clinical features, treatment responsiveness, and prognosis to test the hypothesis that the groups were similar.
METHODS This study was conducted as a retrospective chart review of patients seen at the Montefiore Headache Center from September 2005 to April 2009. All patients were over 12 years of age, although their headache onset may have preceded age 12.
All new patients completed a standardized questionnaire that captures detailed demographic, headache, past medical, social, and family history characteristics [http://www.montefiore.org/ documents / MHC%20New%20Patient%20Questionnaire%20 (with%20allodynia%20-%205-6-08).doc]. As the questionnaire was updated in 2008, the allodynia symptom checklist (ASC), a validated questionnaire for the presence of allodynia, was included, 12 as was the Patient Health Questionnaire (PHQ-9), a validated sensitive and specific screen for major depression. 13 An ASC score Ͼ2 may indicate at least mild allodynia, and a PHQ-9 score Ͼ4 may indicate mild depression. The majority of patients were seen and examined by both a headache medicine fellow and faculty member, and further investigational studies such as neuroimaging, blood tests, and lumbar puncture were requested as clinically indicated to exclude secondary etiologies.
NDPH was diagnosed according to the revised ICHD-2 criteria used recently by Kung et al. 5 We designated these patients as NDPH-R. Patients fulfilling NDPH-R but not the ICHD-2 criteria (because of migraine features) were designated NDPHmf, and patients fulfilling ICHD-2 criteria were designated NDPH-ICHD. All other headache diagnoses were made using the ICHD-2 criteria. Medication overuse was defined as the level of medication intake needed for the diagnosis of medicationoveruse headache. 2 Management decisions were made at the discretion of the treating physicians.
If patients had a history of episodic migraine or episodic tension-type headache (ETTH), they could only be diagnosed with NDPH-R if they had a low baseline headache frequency (less than 4 days of headache monthly) and no clear escalation of headache frequency prior to NDPH-R onset. Patients with other forms of CDH (chronic migraine, CTTH, and hemicrania continua) or clinically suspected of secondary headache disorders, such as post-traumatic headache, spontaneous intracranial hypotension (SIH), and idiopathic intracranial hypertension, were excluded.
We further categorized NDPH-R into 3 temporal profiles: 1) a persisting form with continuous headache from the onset, 2) a remitting form with either a complete remission of the continuous headache or with residual headache occurring less than 5 days per month for at least 3 months, and 3) a relapsingremitting form, defined by periods of continuous headache interspersed with pain-free periods. NDPH-R duration was defined as the time period between headache onset and first visit at our center.
Patient subgroup proportions were compared using a 2-tailed Fisher exact test. Statistical significance was defined as a p value less than or equal to 0.05. This study was approved by Montefiore Medical Center's Institutional Review Board. Written informed consent from patients was not obtained based on the retrospective study design. 
RESULTS Comparison of NDPH diagnostic sub-
types. Seventy-one patients fulfilled NDPH-R. Among them, 43.7% (n ϭ 31) fulfilled NDPH-ICHD and 56.3% (n ϭ 40) did not because they had too many migraine features (NDPH-mf). The features of NDPH-R, NDPH-ICHD, and NDPH-mf are shown in tables 2 and 3.
Demographics. In NDPH-R, patients were predominantly female (71.8%) and white (80.3%). NDPH-mf patients were more likely to be women than were NDPH-ICHD patients (82.5% vs 58.1%, p ϭ 0.033), but there were no significant differences in terms of race (table 2) .
Previous headache history. Overall, 25.4% of patients had a preexisting history of a primary headache disorder, either ETTH (18.3%) or migraine (7.0%). There were no significant differences between sub-groups in their prior history of episodic headaches overall, ETTH, or migraine. Only one patient had a history of episodic migraine with aura, and she was in the NDPH-ICHD group.
Family headache history. Nearly half (49.3%) of NDPH-R patients reported a family history of frequent headaches. There were no significant differences in family history between NDPH-ICHD patients (54.8%) and NDPH-mf patients (45.0%).
Medical and psychiatric comorbidities. Medical comorbidities were reported in 28 patients (39.4%). The most common condition reported was hyperlipidemia (n ϭ 12, 16.9%), followed by hypertension (n ϭ 9, 12.7%), asthma (n ϭ 6, 8.5%), and diabetes (n ϭ 4, 5.6%). Polycystic ovarian syndrome, irritable bowel syndrome, treated hypothyroidism, restless legs syndrome, and obstructive sleep apnea each occurred in 3 patients (4.2%), and 2 patients had fibromyalgia (2.8%).
A preexisting history of psychiatric disorders was significantly more common in NDPH-mf than in NDPH-ICHD for depression (47.5% vs 19.4%, p ϭ 0.02) but not anxiety (42.5% vs 22.6%, p ϭ 0.13). PHQ-9 scores were collected in 18 NDPH-ICHD patients and 19 NDPH-mf patients. The proportion of patients exceeding a cut score of 4 did not differ between the groups (73.7% vs 50%, p ϭ 0.18).
Onset. Onset age ranged from 8 to 76 years, with a median age of 28 years overall, 26 years in women, and 28 years in men (figure e-1 on the Neurology Web site at www.neurology.org). The median onset age was slightly older in NDPH-ICHD (overall: 34 years, women: 34 years, men: 33 years) than in NDPH-mf (overall: 25 years, women: 25 years, men: 21 years). September was the most common month of onset overall and in both subgroups, and a second peak was noted in March for NDPH-R and NDPH-ICHD (figure e-2). Overall, 46.5% recalled a specific trigger, without significant differences between NDPH-ICHD (41.9%) and NDPH-mf (50.0%). The most common NDPH-R trigger was a preceding flu-like or upper respiratory illness (n ϭ 10, 14.1%), followed by a stressful life event (n ϭ 7, 9.9%) and menarche (n ϭ 3, 4.2%). Two patients reported headache onset while selective serotonin reuptake inhibitors (citalopram, sertraline) given for depression were being tapered. One patient experienced symptom onset 2 days after her second vaccination for human papillomavirus. Table 2 displays the clinical features. NDPH-mf patients were more likely to have throbbing pain, nausea, vomiting, photophobia, phonophobia, and aggravation by physical activity. No patients in the NDPH-ICHD group had vomiting. Only 1 patient described symptoms consistent with visual aura (5 to 10 minutes of spreading "white spots" in his vision), which occurred during painful exacerbations; he was in the NDPH-ICHD group. Almost all NDPH-R, NDPH-ICHD, and NDPH-mf patients had bilateral pain (88.7%, 93.5%, 83.0%). Baseline mean level of pain was usually moderate (graded 4 to 6 out of 10) overall and in both subgroups (57.7%, 61.3%, 55.0%).
Clinical features.
Cranial autonomic symptoms associated with painful exacerbations were more likely in NDPH-mf (27.5% vs 12.9%), but this discrepancy was not significant. Interestingly, 4 patients (3 NDPH-ICHD, 1 NDPH-mf) reported frequent episodic bilateral facial flushing with painful exacerbations, usually lasting for a few minutes.
The ASC was completed by 27 NDPH-R patients, 9 NDPH-ICHD patients, and 18 NDPH-mf patients. The mean ASC scores were 1.70, 0.88, and 2.11. However, although ASC Ͼ2 was more common in NDPH-mf (33.3% vs 11.1%), this was not significant.
Imaging. All patients underwent neuroimaging. Sixty-eight patients (95.8%) had a brain MRI, and the remaining 3 patients had a noncontrast head CT scan. Thirty-five patients (49.3%) had contrastenhanced MRI scans as well. MRI abnormalities were scarce, occurring in 5 NDPH-ICHD and 6 NDPH-mf patients. Abnormalities included 5 patients with punctate white matter lesions, 2 patients with white matter ischemic changes, 2 patients with 1-cm pineal cysts, 1 patient with 2 small venous angiomas, and 1 patient with a 1.0-by 0.6-cm right frontal arachnoid cyst. Sixteen patients (22.5%) had lumbar punctures, all of which were normal (including opening pressure) except a slightly elevated protein level of 44 mg/dL in 1 patient.
Treatment. Thirty-four NDPH-R, 12 NDPH-ICHD, and 22 NDPH-mf patients tried at least 1 triptan for headache escalations. NDPH-mf patients were more likely to report some improvement in pain (37.5% vs 16.7%), but this did not reach significance. In some patients nerve blocks with 0.5% bupivacaine were performed in areas tailored to the location of the patient's pain, and included greater occipital, lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blockade. Twentythree NDPH-R patients had nerve blocks (9 in NDPH-ICHD, 14 in NDPH-mf). NDPH-ICHD patients were more likely to report a significant decrease in pain severity for at least 1 day as compared with NDPH-mf patients (88.9% vs 42.9%), but this difference was also not significant. Medication overuse occurred in 45.1% overall, and was similar in NDPH-ICHD (48.4%) and NDPH-mf (42.5%). Ten of the 11 patients (90.9%) with the remitting subform were on preventive medications when their continuous headache pattern broke, the most frequent of which were nortriptyline (n ϭ 6) and topiramate (n ϭ 4). No patient in the relapsingremitting subform was taking preventive medications at the time when the continuous headache pattern broke for the first time.
Prognosis. Overall, 76.1% of NDPH-R had the persisting subform, with similar proportions in NDPH-ICHD (77.4%) and NDPH-mf (75.0%). The relative frequencies of the remitting subform were similar for NDPH-ICHD (12.9%) and NDPH-mf (17.5%) and for the relapsing-remitting subform (9.7%, 7.5%). The median duration of the persisting subform was longer in NDPH-mf (31 months) than in NDPH-ICHD (18 months). A higher proportion of NDPH-mf had headache duration of 24 months or longer (63.3% vs 37.5%), but this was not significant. Of the 11 patients with the remitting subform, the time to remission ranged from 4 months to 54 years, with a median duration of 21 months. Of the 6 patients who had the relapsing-remitting subform, the time to first remission ranged from 3 to 24 months, with a median duration of 5.5 months.
Comparison of NDPH-R prognostic subtypes.
NDPH-R patients were grouped by prognostic subforms. As there were far fewer patients in the remitting (n ϭ 11) and the relapsing-remitting (n ϭ 6) subforms than in the persisting (n ϭ 54) subforms, the remitting and the relapsing-remitting subgroups were combined, labeled as the nonpersisting subform.
Demographics, prior headache history, family history, psychiatric comorbidity, and onset. As shown in table 4, the prognostic subforms of NDPH-R are largely similar in most respects, except that patients in the persisting subform were more likely to be of white race and have a history of anxiety or depression. The median onset was older in the nonpersisting subform overall (34 vs 26 years), for women (34 vs 24 years), but not for men, where it was older in the persisting subform (28 vs 16 years). Patients with the nonpersisting subform were more likely to be of black race, and have a headache onset from age 30 to 39 (35.3% vs 11.1%).
Headache features and treatment aspects. Headache features and treatment aspects are shown in table 5. There were no significant differences among the persisting and nonpersisting subforms in any of the ascertained headache features or treatment aspects. In addition, there were no differences among the prognostic subforms in terms of fulfilling ICHD-2 criteria for NDPH (41.2% of nonpersisting vs 44.4% of persisting subforms).
DISCUSSION
In this study, we examined a large series of patients meeting NDPH-R criteria. We found that the majority of these patients do not fulfill NDPH-ICHD-2 criteria, but do meet criteria for NDPH-mf. Other groups applying comparable criteria have drawn similar conclusions. 14 One possibility is that the ICHD-2 criteria are too restrictive and that the group with migraine features is part of the NDPH spectrum. Another possibility is that the NDPH-R criteria are too loose and we are expanding this rubric beyond its clinical utility. In the current classification, some patients who meet NDPH-mf criteria (those with a history of Ն5 prior attacks of migraine without aura) would be classified as chronic migraine, 15 though they had no history of escalation of headache frequency prior to NDPH onset. NDPH-mf patients without a history of Ն5 prior attacks of migraine without aura would not be classifiable.
We compared the demographic, clinical, and prognostic features of these 2 groups and found that they were substantially similar, particularly in outcome. NDPH-ICHD patients were more likely to recall the onset day or month, and NDPH-mf patients were more likely to be women, have a history of depression or anxiety, and by definition, migraine features. The female predominance and increased comorbidity of depression and anxiety may reflect a stronger biologic connection between NDPH-mf and migraine.
When comparing NDPH patients by their prognostic subforms, there were strikingly few differences among the nonpersisting and persisting groups. The persisting form was present in 77.4% of the NDPH-ICHD-2 and 75.0% of the NDPH-mf groups. The nonpersisting group was more likely to have an onset from age 30 to 39, and the persisting group was more likely to have a history of anxiety or depression, which may relate to a longer duration of illness. The prognosis of NDPH was initially thought to be benign. In Vanast's 6 initial series, 86% of men and 73% of women were headache-free by 24 months. In an Italian series of 18 patients, 66% remitted within 24 months. 11 In our series, we did not follow all patients over a 24-month period, but over half of the patients with the persisting subform had continuing daily headache for 24 months or longer. Of the patients who remitted, 63.6% did so within 24 months. In the relapsing-remitting subgroup, all patients remitted for the first time within 24 months, but relapses inevitably occurred. Our series confirms that in the majority of cases presenting to a tertiary headache center, NDPH can have a protracted course.
The etiology of NDPH is poorly understood. Because of the report that many patients experience an antecedent flu-like illness, a postinfectious phenomenon has been postulated, 16 often attributed to Epstein-Barr virus 17 or other infections. 11 Our finding that NDPH patients can have their headache onset in a biphasic pattern during the beginning of spring and autumn could also impart a seasonal trigger, such as an infection, as a common inciting factor. However, though NDPH patients may have elevated CSF levels of a proinflammatory cytokine, tumor necrosis factor-␣, this does not seem related to having a history of an antecedent infection. 18 Other potential etiologies include stressful life events, cervical joint hypermobility, 19 and defective internal jugular venous drainage. 20 In addition, SIH is an important secondary disorder to exclude, 21 as it can present as NDPH without orthostatic symptoms, 22 often goes undiagnosed, and may result in a long delay of effective treatment. 23 Although we cannot definitively exclude SIH in all our patients, nearly half had gadolinium-enhanced MRI examinations and one quarter had lumbar punctures that showed no evidence of this disorder. Finally, Mack 16 reported that chronic migraine can have an abrupt onset in 30% of children with a prior history of episodic migraine, and often had similar triggers, which was quite similar to NDPH.
Our series also reports new aspects to NDPH that have not been highlighted previously. We report an association of declining selective serotonin reuptake inhibitor dose in 2 patients, possibly reflecting an underlying dysfunctional serotonergic pathway. In addition, we found aura symptoms to be rare, where only one patient had a preexisting history of episodic migraine with aura, and a second patient had aura symptoms with painful exacerbations after NDPH onset. Taken together, this 2.8% of our NDPH patients with aura is far lower than the 30% of patients with migraine 24 and the 5% of the adult population 25 reported to have aura.
Another novel feature that we report includes episodes of bilateral facial flushing in some patients, which could be an associated autonomic or vasomotor symptom. In addition, some patients with NDPH may be triptan-responsive, and although this did not reach significance, NDPH patients with a migraine headache phenotype were more responsive than the group with a TTH phenotype.
Our study has many limitations. Our findings may not be applicable to the general population, as this case series only included patients seen at a single tertiary headache center, and did not include young children. Patients having a form of NDPH that either remits shortly after 3 months or causes little disability may not seek medical attention at all, or at least be less likely to be referred to a neurologist or headache center. Self-reported family histories and psychiatric comorbidities may not be accurate. Fi- nally, as this is a retrospective case series, recall bias is inevitable, although most patients recalled the circumstances of onset rather easily, even though some could not report the specific date of onset.
